KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Depreciation & Amortization (CF): 2014-2024

Historic Depreciation & Amortization (CF) for BeOne Medicines (ONC) over the last 11 years, with Dec 2024 value amounting to $171.8 million.

  • BeOne Medicines' Depreciation & Amortization (CF) fell 47.70% to $37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.9 million, marking a year-over-year increase of 7.30%. This contributed to the annual value of $171.8 million for FY2024, which is 95.91% up from last year.
  • Latest data reveals that BeOne Medicines reported Depreciation & Amortization (CF) of $171.8 million as of FY2024, which was up 95.91% from $87.7 million recorded in FY2023.
  • Over the past 5 years, BeOne Medicines' Depreciation & Amortization (CF) peaked at $171.8 million during FY2024, and registered a low of $31.8 million during FY2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $87.7 million (2023), whereas its average is $108.6 million.
  • Data for BeOne Medicines' Depreciation & Amortization (CF) shows a peak YoY skyrocketed of 95.91% (in 2024) over the last 5 years.
  • Over the past 5 years, BeOne Medicines' Depreciation & Amortization (CF) (Yearly) stood at $31.8 million in 2020, then spiked by 46.14% to $46.5 million in 2021, then spiked by 42.67% to $66.3 million in 2022, then skyrocketed by 32.28% to $87.7 million in 2023, then skyrocketed by 95.91% to $171.8 million in 2024.